Now over 40 years since the initial reports of AIDS, and despite tremendous strides in the development of, and broader global availability to, highly efficacious antiretroviral therapy, global rates of new HIV infections continue at an unacceptably high level. While progress is also being made in developing novel biomedical HIV prevention interventions, an efficacious HIV vaccine will almost certainly be needed to end the AIDS pandemic. However, inherent properties of HIV-including its extraordinarily high levels of genetic diversity, the structural attributes of the viral surface Envelope glycoprotein, the ability of the virus to establish life-long infections, and its capacity to evade, avoid and damage host immune responses-make it the most challenging pathogen to ever confront vaccine developers. Traditional empiric vaccine approaches that have enabled the successful development of vaccines against a wide range of other infectious disease threats have so far failed to deliver an efficacious HIV vaccine. As a result, HIV vaccine research efforts have necessarily required the development of new tools and technologies for vaccine immunogen design, characterization, and evaluation. Without question, the scientific power and sophistication of HIV vaccine approaches have provided tremendous benefits for the accelerated development of vaccines against other global threats, including SARS-CoV-2. Contrasting the pace of HIV versus SARS-CoV-2 vaccine development programs vividly demonstrates how the biological nature of the pathogen being targeted, and how it interacts with the human immune system, as the fundamental determinants of timelines and probability of vaccine development success. Encouragingly, the innovative approaches for rational vaccine design pioneered in the pursuit of HIV vaccine development, in concert with elements emerging from accelerated COVID-19 vaccine development programs, are bringing new hope to efforts to develop an efficacious HIV vaccine itself. In particular, novel strategies for the design and expedited evaluation of HIV vaccine immunogens targeting the elicitation of broadly neutralizing antibodies are providing new directions and promise to the HIV vaccine field. This presentation will review the challenges, disappointments and lessons learned from earlier HIV vaccine development efforts, while also describing innovative strategies now being pursued and encouraging recent progress being made towards an efficacious HIV vaccine.